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Secondary lymphedema is the accumulation of protein-rich fluid in the interstitial spaces of the 
extremities. It typically occurs as a result of a trauma or infection in the lymphatic system. This 
is a significant public health issue because lymphedema has emerged as one of the most 
debilitating consequences of breast cancer treatment and currently no model exists to predict 
who will be affected. The aim of this study was to examine genes that may increase the 
susceptibility to developing secondary lymphedema following breast cancer surgery and/or 
radiation. Perometry and bioelectrical impedance spectrometry (BIS) were also used to examine 
clinical and subclinical swelling in individuals.  
This is a case-control study that sequenced connexin genes of 70 women with secondary 
lymphedema and over 100 control participants without lymphedema. Connexins form gap 
junction channels that facilitate communication between cells. The connexins that were 
sequenced include connexin 47 (GJA12), connexin 37 (GJA4), connexin 40 (GJA5), and exon 2 
of connexin 43 (GJA1). Four missense mutations and one synonymous substitution were 
identified in connexin 47. The mutations were not found to be polymorphic in control 
individuals. The identification of connexin 47 mutations is compelling and warrants further 
research to determine if and how this gene increases the risk of secondary lymphedema after 
breast cancer treatment. These findings could have implications for prevention, management, and 
early diagnosis of breast cancer-associated secondary lymphedema. 
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1.0  INTRODUCTION 
Every year in the United States approximately 200,000 women are diagnosed with breast cancer.  
It is estimated that 80% of these women will survive this diagnosis, with the survival rate 
continuing to improve as treatments improve.1 Because women are now living longer after 
having breast cancer there has been increasing attention on the adverse effects of therapy. 
Current treatment options include surgery, radiation, chemotherapy, and/or hormone therapy. 
Advancements in these therapies have led to successful outcomes for many patients with breast 
cancer. Unfortunately, lymphedema has emerged as a debilitating and devastating consequence 
for a substantial number (~20%) of these individuals.   
Breast cancer-associated lymphedema, which is characterized by an accumulation of 
lymph fluid in the interstitial space of one or both arms, is often attributed to surgery or radiation 
as an iatrogenic side effect. Axillary lymph node dissection is the most common cause of 
lymphedema in the United States.2 As many as one in four women who receive this surgery will 
develop edema of the arm and subsequently be diagnosed with lymphedema.3 Of women who 
are affected, 80% develop it within the first three years after surgery and the remainder develop 
it at a rate of 1% per year.4 It is well recognized that treatment to the axilla, either with surgery 
and/or radiation, is the initiating cause of swelling; however, the mechanistic factors that lead to 
lymphedema for some women but not others are poorly understood.5 The inability to identify 
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predisposing factors has created growing fear and frustration in patients who are at a high risk of 
developing lymphedema by virtue of being treated for breast cancer.6 
Lymphedema is associated with a considerable degree of functional impairment, 
psychological morbidity, and diminished quality of life.7 Many women express frustration with 
the lack of information they received before and after surgery concerning their risks of 
developing lymphedema. This is likely a combined function of the limited scientific evidence 
that is available, and the reduced opportunity for healthcare workers to provide education due to 
minimal postoperative hospital stays.8 Much of the literature regarding the risk of lymphedema is 
centered on severity of disease, extent of surgery, such as axillary clearance versus sentinel node 
biopsy, and the use of chemotherapy or radiation. In the past, it was thought that the trauma of 
treatment was responsible for the pathophysiology of lymphedema;9 however, a study of 200 
patients failed to find a relationship between lymphedema and a number of factors including 
extent of surgery or radiation to the breast, dose of radiation, surgical or radiation complications, 
time since presentation, age, menopausal status, handedness, or drug therapy.9 In addition, a 
review of 36 studies on secondary lymphedema after breast cancer therapy was also unable to 
identify compelling predisposing factors.10 
It is apparent that there is a lack of understanding of why women develop lymphedema 
after breast cancer treatment. Preventative measures such as the avoidance of infection, injury, 
and arm constriction are often recommended based on anecdotal evidence, but scientific 
verification is still lacking and these measures do not guarantee that a woman will remain 
symptom-free.11 Many studies have attempted to identify factors that increase or decrease a 
woman’s risk with little success. Obesity and infection are the only two factors that are 
consistently associated with secondary lymphedema, but they still do not explain the majority of 
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cases.12; 13 At the present time, there is no cure for lymphedema, but it is important to identify 
women in the early stages of the condition in order to better manage the swelling and prevent it 
from progressing to the later stages. Examining mechanisms that have not received much 
attention, such as inherent lymphatic variation and genetic etiology, may lead to the development 
of screening tools that could help to identify women at the greatest risk for this debilitating 
condition.    
1.1 PATHOPHYSIOLOGY OF LYMPHEDEMA 
The lymphatic system functions to remove waste material and excess fluid from tissues 
throughout the body. It consists of small lymphatic capillaries where interstitial fluid is initially 
drained from the tissues, larger precollector vessels, collecting lymphatic vessels in which the 
precollectors drain, and lymph nodes. The lymphatic capillaries are distributed throughout the 
tissue spaces and are formed as interconnected branches. The lymphatic capillaries do not have 
an obvious opening for lymph fluid to enter, but instead are made up of single cells that overlap 
in a way that causes them to separate slightly when pressure from interstitial fluid is present. 
These openings allow fluid into the capillaries, but do not allow it to leak back out. One-way 
valves are present to keep the flow of fluid unidirectional away from the tissues and into the 
collecting lymphatic vessels. The afferent lymphatic vessels utilize one-way valves and smooth 
muscle contractions to propel lymph fluid to the lymph nodes where it is filtered then returned to 
the circulatory system via efferent lymphatic vessels. 
Lymphedema develops when there is a failure within the lymphatic system. This can 
occur due to rare congenital malformations in the lymph pathway, referred to as primary 
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lymphedema, or as a result of outside trauma such as surgery or an infection, which is referred to 
as secondary lymphedema. The pathophysiology of primary lymphedema is not completely 
understood, but is thought to result from congenital or acquired malformations such as lymph 
vessel hypoplasia or aplasia, atrophy of the smooth muscle layer within the vessels, or 
hyperplastic lymph vessels.   
The pathophysiology of secondary lymphedema depends on the cause of the lymphedema 
and is still not fully known for most cases. In less developed parts of the world secondary 
lymphedema is often caused by filariasis, a parasitic worm that obstructs the lymphatic system 
and can reduce lymphatic contractility. Other cases of secondary lymphedema are precipitated by 
lymphangitis, a bacterial infection of the lymph vessels, and cellulitis, a bacterial skin infection. 
If these conditions are recurrent they can lead to progressive destruction of the lymphatic 
vessels.14  
Cancer treatment, specifically surgery and/or radiation, is the most common cause of 
secondary lymphedema in developed countries.14 It is thought that the trauma of surgery or 
radiation to the axilla interrupts the lymphatic drainage pathways from the arm. This creates a 
rise in lymphatic pressure with subsequent lymphatic dilation. If the lymph system is 
overwhelmed by the influx of fluid or if the valves are incompetent, fluid is less likely to move 
in the appropriate unidirectional manner and backflow can develop towards the skin. The 
inability to clear protein from the interstitial fluid combined with a reduction in the colloid 
osmotic pressure gradient results in continued leakage of fluid from the capillaries until the 
interstitium reaches a new equilibrium.15 
Postoperative arm swelling is not uncommon following surgery and is likely a result of 
trauma as described, but it tends to resolve spontaneously after a few weeks.14 Lymphedema, 
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however, develops months to years after treatment, with sudden or gradual onset.15 Because of 
this delay in lymphedema development and the fact that nearly 75% of women do not experience 
it, the explanation based solely on trauma of treatment is insufficient and leaves many questions 
still unanswered. Several studies have attempted to create an animal model of surgery-induced 
lymphedema without much success. Transient edema in a canine model has been produced after 
transection and resection, but was found to resolve within 2-4 weeks.16 Surgical ablation with 
irradiation produced lymphedema more reliably in canines, although it was not present in every 
case and it required far greater surgical trauma than what is involved in breast cancer treatment.17 
These results further support the idea that other variables are likely playing a role in the 
development of lymphedema beyond the interruption of the lymphatics because of surgery.   
More recently, clinical studies of patients with lymphedema have indicated that inherent 
variation in lymphatic function may predispose an individual to secondary lymphedema. 
Investigations of lymphatic clearance rates using lymphoscintigraphy reveal abnormalities in the 
“normal” contralateral arms of breast cancer survivors who have developed lymphedema, further 
suggesting that genetic susceptibility may play a role in the development of secondary 
lymphedema.18; 19  
1.2 DIAGNOSIS  
The true incidence of secondary lymphedema following breast cancer treatment is difficult to 
determine because of the variety of diagnostic methods and definitions currently being used by 
clinicians and researchers. Universal standards for the diagnosis of secondary lymphedema have 
yet to be established. Currently, the gold standard for lymphedema diagnosis is 
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lymphoscintigraphy. It is also helpful in differentiating between lymphedema and other causes of 
edema such as heart, renal or hepatic failure, venous thrombosis, phlebitis, chronic venous 
insufficiency, and lipedema.20 Lymphoscintigraphy is performed by injecting a water-soluble 
colloidal radiotracer subcutaneously into a patient’s hand or foot.  A gamma camera is then used 
to capture serial images of the path of the radiotracer through the lymphatic vessels in order to 
monitor the flow of lymph fluid. This method is the most effective technique for imaging the 
structure and function of the lymph system, but it is not ideal for routine clinical practice.21  
 There are a number of other existing procedures used to aid in the diagnosis of 
lymphedema which include: (1) limb girth via tape measurements, (2) water displacement, (3) 
perometry, and (4) bioelectrical impedance. Taking physical measurements at specified points 
along the limbs can be performed in many different settings and is useful for continuous 
monitoring; however, the assessment of secondary lymphedema may require more sensitive 
modes of measurement to identify it earlier. Water displacement techniques correlate well with 
physical measurement22, but are difficult to perform and may not be practical in every clinical or 
research setting.  
Perometry is an automated method of determining limb volume that utilizes infrared light 
transmitters and photo sensors inside a moving frame. The frame takes measurements every half-
centimeter along the length of the limb. Perometer measurements are less likely than physical 
measurements to be affected by inter-operator variability and have been found to be consistently 
reproducible.23; 24 Bioelectrical impedance spectrometry (BIS) is another automated technique 
that has shown promise for quantitatively measuring lymphedema in patients with breast 
cancer.25 BIS is based on the principle that as the fluid volume in the extremities increases, the 
impedance to electrical current decreases. Further research is necessary, but BIS could prove to 
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be the most effective and convenient method for early detection of breast cancer-related 
lymphedema. In addition, BIS assesses extracellular water content, which is thought to be the 
earliest sign of lymphedema.26 Although advances have been made in technology available to 
measure the limbs of women at-risk for developing secondary lymphedema, the question still 
remains as to whether these measurements have the ability to detect phenotypic differences 
between women who will develop lymphedema and those who will not. 
1.3 TREATMENT AND MANAGEMENT 
For many women who experience edema after breast cancer surgery the swelling resolves 
without the need for treatment. Women who do eventually develop irreversible lymphedema 
require immediate treatment and consistent management for life. Compression bandaging is 
often the first step in managing fluid accumulation. Compression bandages provide a low amount 
of pressure at rest and enhance the clearance of lymphatic fluid during muscle movement. As 
swelling progresses it is often necessary for a woman to be fitted for a compression sleeve. 
Patients with mild lymphedema use compression sleeves in order to maintain volume reduction 
in the affected limb. The sleeves are custom fitted for the patient’s arm and wrist and function to 
apply approximately 20-60 mmHg of pressure.27  
In addition to near constant compression, specially trained massage therapists or physical 
therapists can perform gentle massage known as manual lymphatic drainage (MLD). The goal of 
MLD is to stimulate the flow of lymph fluid and direct it from areas of stasis to the functioning 
lymphatics for clearance. The most common treatment plan for a woman after a diagnosis of 
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lymphedema involves a combination of the previously mentioned therapies along with patient 
education, meticulous skin hygiene, and exercises.27 
If left untreated, lymphedema will progress through three well-defined stages. Grade 1 
lymphedema is typically mild and is managed successfully with physical therapy. At this point in 
development the skin will appear to pit when pressure is applied. Grade 2 lymphedema is 
characterized by changes in the affected tissue that include hardening of the skin and an increase 
in fibrous tissue. Patients with grade 2 lymphedema are at an increased risk for infections and 
experience a decrease in the efficacy of therapeutic interventions. The final stage, grade 3 
lymphedema, is the most profound and is commonly referred to as lymphostatic elephantitis. It 
occurs when the affected limb is left untreated. Limb function is significantly compromised and 
excess skin may appear to hang in folds. Less than 1% of patients will develop 
lymphangiosarcoma, a dangerous malignancy, or another secondary tumor.15 
1.4 GENETIC ETIOLOGY OF LYMPHEDEMA 
Investigation into the potential genetic etiology of secondary lymphedema after breast cancer 
treatment began in response to the identification of genes responsible for the onset of primary 
lymphedema. Many genes are involved in lymphatic development, but only three are known to 
play a role in primary lymphedema. Mutations in FLT4 (VEGFR3), FOXC2, and SOX18 are 
associated with Milroy disease28; 29, lymphedema-distichiasis syndrome30, and hypotrichosis-
lymphedema-telangiectasia31 respectively. The majority of affected individuals and families, 
however, do not have a mutation in these genes and researchers are continuing to search for 
others that may be involved. 
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Milroy disease (congenital lymphedema) is well characterized as a type of primary 
lymphedema that presents with lower limb lymphedema at birth or early in childhood. The 
swelling is often bilateral and symmetric, but the severity varies between individuals and within 
families. Milroy disease is inherited in an autosomal dominant pattern with approximately 85-
90% of individuals with a FLT4 mutation developing the condition before the age of three.32 The 
FLT4 gene is located on chromosome 5q35.5. It encodes the vascular endothelial growth factor 
receptor-3 (VEGFR3) protein, a tyrosine kinase receptor for vascular endothelial growth factors 
C and D that is thought to be involved in lymphangiogenesis and maintenance of the lymphatic 
endothelium. 
Lymphedema-distachiasis syndrome is another autosomal dominant primary 
lymphedema condition that presents with lower limb lymphedema and distichiasis. Other 
associated features include varicose veins, congenital heart disease, ptosis, and ocular findings 
such as corneal irritation, recurrent conjunctivitis, and photophobia.33 Approximately 25% of 
individuals are asymptomatic. Distichiasis is often present at birth and lymphedema develops 
between late childhood and puberty. Sequence analysis of the FOXC2 gene detects 95% of 
mutations in individuals who have been clinically diagnosed with lymphedema-distachiasis. 
FOXC2 is located on chromosome 16q24.3 and it encodes the forkhead box protein C2. This 
protein functions as a transcriptional regulator during embryonic development and is expressed 
in adult adipose tissue and lymphatics.34 FOXC2 mutations have also been implicated in 
phenotypes attributed to other lymphedema syndromes.35   
Other primary lymphedema conditions include hypotrichosis-lymphedema-telangiectasia 
syndrome, Meige disease (lymphedema praecox), and lymphedema with yellow nails. 
Hypotrichosis-lymphedema-telangiectasia syndrome is characterized by lower limb 
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lymphedema, hair loss, and telangiectasias. It is very rare and has been found to be caused by 
mutations in the SOX18 gene in both an autosomal dominant and recessive inheritance pattern.31 
Meige disease primarily affects women during puberty, and lymphedema with yellow nails often 
develops in individuals over the age of 50. Genes have not been identified in association with 
these two conditions. 
Because several genes function together during lymphangiogenesis and lymphatic 
endothelial maintenance it is likely that other genetic pathways are involved in primary 
lymphedema. These same pathways may also contribute to a predisposition to developing 
secondary lymphedema after surgery for breast cancer. The recent identification of mutations in 
the hepatocyte growth factor receptor MET (HGF/MET) pathway has provided evidence for a 
parallel mechanism contributing to both primary and secondary lymphedema. Finegold et al. 
(2008) discovered a MET mutation that is shared in patients with breast cancer-associated 
secondary lymphedema and patients with primary peripheral and intestinal lymphangectasia.36 
This same research group has found that among 239 individuals with both a diagnosis of primary 
lymphedema and a family history of lymphedema, 5% have mutations in the VEGFC/VEGFR3 
pathway and 7% have mutations in FOXC2. HGF/MET mutations likely contribute to a similarly 
small proportion of individuals with lymphedema.36 It is possible that alterations in any of these 
known lymphedema pathways and those that have yet to be described could account for an 
increased risk for secondary lymphedema in certain patients undergoing treatment for breast 
cancer, consistent with the findings in HGF/MET. 
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2.0  SPECIFIC AIMS 
Specific Aim 1: To examine additional genes that may predispose a woman to developing 
secondary lymphedema following breast cancer surgery.  
Hypothesis: Women with breast cancer-associated secondary lymphedema will have previously 
unrecognized variations in connexin genes that will not be found in women who do not develop 
lymphedema.  
We chose to sequence a selection of the gap junction genes including connexin 47 
(GJA12), connexin 37 (GJA4), connexin 40 (GJA5), and exon 2 of connexin 43 (GJA1). 
Connexins are a very complex family of genes. Their functional end products, gap junctions, 
serve as intercellular conduits or channels that provide electronic and metabolic communication 
between cells. There are approximately 20 different types of connexins that cluster together to 
form gap junctions. A single gap junction channel can be comprised of multiple connexin 
subunits and the types of connexins determine the permeability, conductance, and mode of 
regulation of the channel.37 Gap junctions are found in a wide variety of tissues and have been 
implicated in numerous developmental processes. The connexin genes are regulated at the 
transcriptional, translational, and posttranslational levels although the mechanisms by which they 
maintain tight regulation across cell types are not currently understood.38 This study is the first to 
examine the role that gap junctions may play in the onset of secondary lymphedema. 
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Specific Aim 2: To examine the arm volumes of participants with and without secondary 
lymphedema using bioelectrical impedance spectrometry (BIS) and perometry.  
Hypothesis: Participants with lymphedema will have increased fluid and volume measurements 
in the affected arm compared to the contralateral unaffected arm. Participants who have not 
developed lymphedema are not expected to exhibit measurement differences between arms, 
although BIS may detect subclinical swelling in individuals who later develop lymphedema. 
 BIS and perometry are sensitive techniques to investigate swelling in the limbs. Our aim 
was to examine these measurements in affected and at-risk arms compared to contralateral arms. 
We were also interested in examining results of participants who were unaffected at the time of 
measurement but later developed lymphedema. 
BIS is a relatively new tool to measure fluid volume, and it may be able to identify 
subclinical swelling earlier than other techniques. BIS utilizes electric current passed through 
specific regions of the body to measure the impedance to flow. The amount of impedance is 
inversely proportional to the volume of fluid in the tissue. Data for bioelectrical impedance 
measurements is recorded over a frequency range of 4-1,000 kHz with a bioimpedance 
spectrometer (SFB7, Impedimed Ltd., San Diego, CA). Low frequencies (<30 kHz) travel 
through extracellular fluid and high frequency currents travel through intracellular fluid. 
Impedimed software is used to process the data and provide values for the resistance of 
extracellular water (Ro), resistance of total tissue fluid (R∞), and resistance of intracellular water 
(Ri). For the assessment of lymphedema we are primarily interested in extracellular fluid, which 
is optimally measured at zero frequency (R0). At R0 current is unable to penetrate cell 
membranes and is forced to move around the cells. Practical limitations exist, however, that 
prevent a direct measure of resistance at R0. BIS uses data collected over the range of 
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frequencies to extrapolate impedance at R0. Across each frequency two components of 
impedance are measured, resistance (opposition to the current from fluid in the body) and 
reactance (opposition to the current due to cell membranes and tissue).39 To estimate R0 
reactance is plotted against resistance on a Cole plot (Figure 1). Unilateral arm swelling or 
lymphedema is assessed with a relative index of extrapolated R0 values comparing the affected 
to the unaffected limb, or in the case of this study comparing the at-risk limb to the limb that is 
not at risk for lymphedema.39 
 
 
Figure 1. A Cole plot illustrating the relationship between impedance (Z), resistance 
(R), and reactance (Xc). 
Bioelectrical impedance spectrometry (BIS) measures impedance to flow of electric  
current through regions of the body to estimate fluid volume. Extracellular fluid is 
optimally measured at zero frequency (R0), which must be estimated based on reactance 
and resistance plotted on a Cole plot. 
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Perometry operates on an optoelectronic system that uses infrared light beams to take 
measurements and calculate volume. The perometer is composed of a four-sided frame that 
moves along a rail in the long axis of the limb being measured. Light transmitters are located on 
two sides of the frame and project light towards photosensors on the opposing sides (Figure 2). 
The light transmitters are activated when a limb is placed inside the frame and blocks the 
transmission of light. The perometer creates a series of electronic images every half-centimeter 
along the limb in order to calculate volume (Fig. 2). 
 
 
Figure 2. The perometer frame and computer generated image from perometer 
data. 
The perometer uses infrared light beams to take measurements every half-centimeter  
along the limb and calculate volume. Information collected from the perometer is 
displayed as an image on the computer. 
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3.0  MATERIALS AND METHODS 
3.1 STUDY DESIGN 
This study is designed as a case-control study of women who have been treated for breast cancer. 
It was approved by the Institutional Review Board of the University of Pittsburgh. Cases are 
defined as women who have been diagnosed with lymphedema, and controls are defined as 
women who are at-risk for developing secondary lymphedema but have not developed it at the 
time of analyses. The control participants are considered to be at-risk because they have had 
breast cancer surgery. Participants were recruited from Magee-Womens Hospital.   
DNA from two cohorts was sequenced in an attempt to identify mutations in the connexin 
genes. The first group (Group A) consists of individuals who received breast cancer treatment 
between the years of 1988 and 1999. This provided a retrospective look at the development of 
lymphedema.  The second group (Group B) consists of individuals who received breast cancer 
treatment in the past four years, which represents a prospective view of lymphedema 
development.  
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3.2 PARTICIPANTS 
Potential participants in the first retrospective group (Group A) were sent letters from Magee-
Womens Hospital and were contacted by phone if they responded with an interest in 
participating (as described in a master’s thesis presented by Roxanne Miller, 200340). 
Participants were eligible to participate if they had a breast cancer diagnosis between 1988 and 
1999. Letters were sent to 160 potential cases and 500 controls from the Physical Therapy and 
Medical Records departments at Magee-Womens Hospital. A total of 69 cases and 65 controls 
were recruited. Medical and family histories were obtained and participants were asked to 
provide a 30cc blood sample and/or a buccal swab. They were also asked to complete a 
questionnaire and a medical release form to verify the type of breast cancer treatment and the 
diagnosis of lymphedema when applicable. Sequencing of the connexin genes was analyzed for 
59 cases.  
Participants in the second group (Group B) were recruited from flyers posted in Magee-
Womens Hospital, referred by oncology physicians, and were approached in the Medical and 
Surgical Oncology departments by researchers to determine interest in participating. Women in 
the medical oncology suite were approached if they had signed the research registry consent 
form indicating that they were receptive to learning about research studies. Researchers spoke 
with women in the surgical oncology office after a nurse or physician obtained permission. 
Women between the ages of 18 and 100 were eligible if they had undergone surgery for breast 
cancer within the past four years. Family members between the ages of 18 and 100 were also 
eligible to participate, although we only included those who have had a personal history of breast 
cancer (n=4) in this analysis. Interested individuals were given information about the study and 
were scheduled to have limb measurements in the Clinical Research Center (CRC) of Magee-
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Womens Hospital. A total of 77 women participated in the study (n=52 controls, n=15 cases, 
n=10 unsure). Participants were classified as “unsure” if they reported having symptoms of 
lymphedema, but had not been clinically diagnosed at the time of data analysis.  
During their appointment at the CRC participants were asked to sign the consent form, 
complete a medical history questionnaire and medical release form, and provide information 
about their family history. They also provided either a mouthwash sample or a 30cc blood 
sample. Participants had their blood drawn by a CRC phlebotomist or by a nurse in the 
chemotherapy suite in the Department of Medical Oncology. Limb measurements were 
performed with assistance from the nurses in the CRC and included physical measurements with 
a tape measure, perometry, and bioelectrical impedance. Sequencing of the connexin genes was 
analyzed for 35 women from this group (n=11 cases, n=24 controls). 
3.3 LABORATORY PROCEDURES 
DNA was isolated from EDTA anti-coagulated peripheral blood by the salting out procedure as 
described by Miller et al. (1988).41 Amplification and sequencing primers were generated based 
on reported human connexin cDNA sequences. Sequences were downloaded from GenBank 
(accession numbers NM_010288, NM_002060, NM_005266, and NM_020435). Primers 
flanking each exon were designed to amplify the target sequences.  The following primers were 
used to screen the coding exons of the connexin genes: 
Connexin 43 (GJA1), exon 2 only: 2F, 5’-TGGGACAGGAAGAGTTTGCA-3’ with 2R, 5’-
GCCAGGGACACCAAGGACAC-3’ and 2F2, 5’-TGCTGCGAACCTACATCATCA-3’ with 
2R2, 5’-CACCGGATCAAAATTAACACCTG-3’ (53°C Ta; 1.75 mM Mg++) 
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Connexin 37 (GJA4): 2F, 5’-CGAACGAGAAGGATGCCA-3’ with 2R, 5’-
GATGAAGATGGTCTTCTCC-3’ (54°C Ta; 1.5 mM Mg++) and 2F2, 5’-
GTGTTTGTGTGCCAGCGA-3’ with 2R2, 5’-CCAGGCAGCCAGACTTCT-3’ (54°C Ta; 1.5 
mM Mg++) 
Connexin 40 (GJA5): 2F, 5’-CCATTGGATGGATGGATC-3’ with 2R, 5’-
CCGTAGATGAAGTACTGG-3’ (54°C Ta; 1.5 mM Mg++) and 2F2, 5’-
GGAAGGGAATGGAAGGAT-3’ with 2R3, 5’-CAGTTCAGAAGGGACACG-3’ (54°C Ta; 1.5 
mM Mg++) 
 Connexin 47 (GJA12): 2F, 5’-AGGCGGTAAGCTCCACGTCATT-3’ with 2R7, 5’-
CAGTGGTGACCAAGCCAG-3’ (59.6°C Ta) 
The amplimers were treated with shrimp alkaline phosphatase and Exonuclease I then 
sequenced in both directions using ABI Big Dye 3.1 chemistry (Applied Biosystems, Foster City, 
California 94404). An ABI 3730 DNA analyzer was used to sequence the fragments, and the 
sequences were aligned with Sequencher V5.0 software (Gene Codes Corp., Ann Arbor, 
Michigan 48108). 
3.4 MEASUREMENT PROCEDURES 
3.4.1 Bioelectrical Impedance 
In order to control for variation in fluid levels due to external factors, participants were instructed 
to refrain from caffeine and alcohol at least 12 hours before their appointment and not to engage 
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in strenuous activity or exercise at least two hours beforehand. BIS was performed according to 
methods previously described.39; 42  
To summarize, participants were asked to remove all jewelry from their wrists and ankles 
and to lie in a supine position on a non-conductive bed. Arms were placed pronated and slightly 
abducted with no skin-to-skin contact. Skin on the wrists, hands, ankles, and feet were cleansed 
with an alcohol swab before the surface electrodes were attached. We used bony landmarks to 
standardize the placement of the electrodes. Arm impedance was measured from the wrist to the 
axilla.  As illustrated in Figure 3, the current drive electrodes were attached to the dorsal surface 
of the third metacarpal of the hand and the dorsal surface of the third metatarsal of the foot. 
Voltage sensing electrodes were fixed on the dorsum of the wrists midway between the styloid 
processes. The measurement was performed on the right and the left arm.  
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Figure 3. Placement of bioelectrical impedance spectrometry (BIS) electrodes. 
The placement of electrodes determines the limb that is being measured with BIS. Arm 
impedance is measured by placing the current drive electrodes on the dorsal surface of 
third metacarpals and the dorsal surface of the third metatarsals. Voltage sensing 
electrodes are fixed to the dorsum of the wrists midway between the styloid processes. 
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3.4.2 Perometry 
Perometry (Perometer 1000M, Juzo) was performed with the participants standing and reaching 
towards the middle of the frame. They were instructed to reach down until their middle finger 
touched the hand rest and to keep their arm as vertical and straight as possible. The frame was 
lifted in a slow consistent motion up the arm then lowered back down. Measurements were 
obtained for both arms. 
3.5 STATISTICAL ANALYSIS 
Data analysis was performed using SPSS version 17.0 for Mac OS. Descriptive statistics and 
frequency distributions were obtained for each variable of interest. All descriptive statistics for 
Group A were provided by the master’s thesis of Miller (2003).40 Independent t-tests for Group 
B were conducted to examine demographic differences between the cases and controls. Fisher’s 
exact tests were performed to examine differences in potential risk exposures associated with 
secondary lymphedema between cases and controls. To investigate the total number of 
exposures, an analysis of variance (ANOVA) was performed using the reported number of 
exposures as the dependent variable and the lymphedema classification (case, control, or unsure) 
as the independent variable. ANOVAs were also conducted to compare measurement data. When 
applicable, post-hoc analyses were conducted with Tukey’s post-hoc test. Pedigree analysis was 
performed using Progeny V6.0 software.  
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4.0  DATA ANALYSIS 
4.1 DESCRIPTIVE STATISTICS 
Demographic information including ethnicity, age at breast cancer diagnosis, and body mass 
index (BMI) are provided in Table 1 and Table 2 for Groups A and B, respectively. Independent 
t-tests shown in Table 3 revealed that the age of breast cancer diagnosis was significantly higher 
for cases than for controls in Group B (p<0.05). BMI was not significantly different between 
cases and controls (p>0.05); however, cases tended to have a higher BMI than controls. 
According to the National Heart, Lung, and Blood Institute (www.nhlbi.nih.gov), BMI 
measurements of 19-24.9 are classified as normal, the range of 25-29.9 is considered overweight, 
and obesity is in the range of 30-39.9. The average BMI for cases was 31.39, which is considered 
obese. Obesity is a commonly reported risk factor for lymphedema. 
Table 1. Group A demographic variable means. 
 Cases n=69 
Controls 
n=65 
Ethnicity (% Caucasian) 86% 97% 
Age at breast cancer 
diagnosis  52 51 
BMI (kg/m2) 29 27 
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Table 2. Group B demographic variable means and standard deviations. 
 Cases n=15 
Controls 
n=52 
Unsure 
n=10 
Ethnicity (% Caucasian) 14/15 (93%) 50/52 (96%) 9/10 (90%) 
Age at breast cancer 
diagnosis (SD) 57.3 (8.9) 52.0 (8.4) 50.6 (10.9) 
BMI (SD) 31.4 (6.1) 28.2 (5.4) 32.0 (6.4) 
 
Table 3. Group B independent t-tests for equality of means of demographic variables. 
 Group Assignment n Mean Std. Deviation t p 
Age at breast 
cancer diagnosis 
      
Cases 
Controls 
 
15 
52 
57.27 
52.04 
 
8.87 
8.36 
 
-2.11 0.039* 
BMI  Cases Control 
15 
52 
 
31.39 
28.21 
 
6.09 
5.41 -1.90 0.061 
*p<0.05 (2-tailed) 
 
  The timing of the onset of secondary lymphedema after surgery is separated into the 
following three categories:  0 to 3 months, 3 months to 1 year, and more than 1 year following 
surgery. We combined the groups to determine the distribution of lymphedema onset. 
Approximately 28.6% of cases developed lymphedema 0 to 3 months after surgery, 33.7% 
developed it 3 months to 1 year after, and 37.7% developed lymphedema more than one year 
after surgery. It is apparent that women are still at risk after one year, which limits the 
classification of participants into cases and controls in Group B because many are still within one 
year of their surgery (Figure 4). It is possible that in the future more participants will be 
reclassified as having developed lymphedema, which may alter our analyses. 
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Figure 4. Group B time after breast cancer surgery. 
Participants in Group B were asked how long it has been since their breast cancer 
surgery. The majority of women (81.8%) are still within one year of surgery. Fewer 
participants (11.7%) underwent surgery in the past one to three years and 6.5% reported 
having surgery more than three years ago. 
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Information was also collected from participants in Group B regarding exposures to risk 
factors that women are advised to avoid after breast cancer surgery. Participants were asked to 
recall and indicate “yes” or “no” if they had any of the listed exposures following surgery in the 
arm that is at-risk for lymphedema. The at-risk arm is defined as the arm on the same side as 
breast cancer surgery was performed. As illustrated in Table 4, there was no significant 
difference in exposures between cases, controls, and those who were classified as being unsure 
of their lymphedema status. In addition, participants were not significantly different in the 
number of risk factors reported (Table 5). 
Table 4. Participant recall of risk factor exposure. 
 Cases n=15 
Controls 
n=51 p 
Blood pressure 2  9 1.0 
Blood draw 2 9 1.0 
Manicure 3 14 0.74 
Sunburn 1 4 1.0 
Cut 5 12 0.51 
Insect bite 5 8 0.15 
Cat scratch 2 4 0.61 
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Table 5. Analysis of the number of risk exposures reported. 
Group 
Assignment n 
Mean number of 
exposures reported Std. Deviation F p 
      
Cases 
Controls 
Unsure 
 
15 
51 
10 
1.33 
1.18 
1.20 
 
1.45 
1.42 
1.03 
 
0.075 0.93 
 
4.2 RESULTS 
4.2.1 Gene Sequencing Analysis 
Sequence analysis of connexin 47 (GJA12), connexin 37 (GJA4), connexin 40 (GJA5), and exon 
2 of connexin 43 (GJA1) has been completed on 59 cases in Group A and 11 cases and 24 
controls in Group B. The analysis revealed five different nucleotide changes in connexin 47 
(GJA12) that have not previously been described in patients with secondary lymphedema (Table 
6). Connexin 47, located on chromosome 1q41-q42, encodes a 439-amino acid protein. The 
amino acids involved with the changes are illustrated in Figure 5. No nucleotide changes were 
identified in connexin 37, connexin 40, or exon 2 of connexin 43. 
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Table 6. Connexin 47 mutations identified in individuals with or at-risk for secondary 
lymphedema. 
 
*Mutations also identified in individuals with primary lymphedema.  
  
                                     
 
 
          
                                
              
                                  
Mutation 
No. Participant # (group) Location 
Nucleotide 
change 
Amino acid 
change 
Frequency 
in controls 
1 1(A)* cDNA bp 445 G ? A G 149 S 0/194 
2 2(A) cDNA bp 556 G ? T G 186 C 0/210 
3 3(A) cDNA bp 1234 C ? T H 412 Y 0/138 
4 4(A) cDNA bp 1150 C ? T P 384 S 0/137 
5 5(A), 6(A), 7(A), 8(A), 9(A), 10(B), 11(B)* cDNA bp 594 C ? T H 198 H 1/35 
Figure 5. Amino acid structures. 
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Four of the nucleotide changes (No. 1-4) are missense mutations that lead to an amino 
acid substitution in participants from Group A. The peptides involved do not appear to be 
conserved across species. The mutation found in participant 1(A) has also been seen in an 
individual with primary lymphedema. One of the nucleotide changes (No. 5) did not alter the 
amino acid and is likely a synonymous substitution; however, it is not listed in the public 
databases as a polymorphism present in the population (HapMap, dbSNP). The synonymous 
substitution was found in five participants with secondary lymphedema from Group A and two 
participants who are at-risk for lymphedema but have not developed it from Group B. It has also 
been identified in 9 out of 140 individuals with primary lymphedema. 
Mutation No. 1 changes a glycine to a serine at amino acid 149 (G149S). This change 
was found in a woman with secondary lymphedema who has no other family history of 
secondary lymphedema, although of her 10 siblings she is the only one to have undergone breast 
cancer treatment.  She did report that her brother and father suffered from swelling in the feet, 
which may or may not be an indication of primary lymphedema. The mutation was also 
identified in a woman with primary lymphedema and her unaffected son. Her family history is 
significant for lymphedema praecox.  
The second mutation (No. 2) changes a glycine to a cysteine at amino acid 186 (G186C). 
The mutation was found in a participant with secondary lymphedema who has no other family 
history of lymphedema or breast cancer. Mutation No. 3 results in a substitution of histidine for 
tyrosine at amino acid 412 (H412Y). This change was identified in an individual with secondary 
lymphedema who reports having a sister with breast cancer without lymphedema. Mutation No. 
4 was identified in an individual with secondary lymphedema and distichiasis, but with no other 
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family history of lymphedema or breast cancer. This nucleotide change substitutes a proline for a 
serine at amino acid 384 (P384S).  
The synonymous substitution (No.5) was identified in the following participants from 
Group A: three affected women with a family history of breast cancer and no family history of 
secondary lymphedema, one affected woman without a family history of breast cancer, and one 
affected woman who reports having a brother and father with secondary lymphedema and a 
paternal uncle with primary lymphedema. The participants from Group B who were found to 
have the substitution have not developed secondary lymphedema and they do not have a family 
history of breast cancer or lymphedema. Table 7 describes the families of the individuals with 
primary lymphedema found to have the H198H synonymous substitution. 
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Table 7. Description of patients with primary lymphedema and the H198H synonymous 
substitution. 
Family 
number 
Primary lymphedema condition 
of proband Family members affected with lymphedema 
1 
Congenital lymphedema, 
pulmonary lymphangiectasia, 
hydrops 
Proband and sibling died from this 
condition 
2  Lymphedema praecox Mother, maternal grandfather, maternal great grandmother 
3 Lymphedema tarda (late-onset) with yellow nails 
Mother, 2 sisters, brother, and niece with 
lymphedema tarda without yellow nails 
4 Lymphedema praecox Mother with lymphedema praecox and daughter with congenital lymphedema 
5 Congenital lymphedema Son and maternal aunt 
6 Congenital lymphedema Brother, nephew, cousins 
7 Congenital lymphedema 
Sister with lymphedema, paternal uncle and 
paternal grandmother unaffected but with 
ptosis 
8 Congenital lymphedema Brother 
9 Lymphedema praecox 
Sister, mother (with distichiasis), 3 
maternal aunts (1 with yellow nails), 
cousins, maternal grandmother 
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4.2.2 Measurement Analysis 
The BIS and perometer data are described in Table 8. BIS measurements were analyzed by 
creating a ratio of the unaffected (or not-at-risk) arms to the affected (or at-risk) arms. The 
ANOVA results comparing the impedance ratios of cases, controls, unsure participants, and 
cases without lymphedema at the time of measurements are shown in Table 9. A post-hoc test 
revealed that cases had a significantly higher impedance ratio, indicating increased fluid volume 
in the affected arm, compared to controls and unsure participants (p<0.05). The impedance ratios 
of cases with lymphedema at the time of measurements were not significantly different from 
those who had yet to develop lymphedema (p>0.05); however, these results should be interpreted 
with caution because of the small sample size and limitations in the power of the analysis. 
Perometer measurements were compared by obtaining the mean differences between the 
unaffected (not-at-risk) and the affected (at-risk) arms for each group. The mean differences 
were not statistically different between groups, but the trend indicated that the cases had a greater 
difference between arms than the unsure participants, with the controls having the smallest 
difference between arms. Limitations exist, however, that complicate the interpretation of this 
data. It has been well established that arm dominance is a significant factor and should be 
considered when comparing the right and the left arms. The dominant arm is typically larger than 
the non-dominant arm within the range of 1.5% - 4.2%.25 Unfortunately, we only have arm 
dominance information for seven control participants, and are not able to control for arm 
dominance in these analyses.  
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Table 8. BIS and perometer measurement means and standard deviations. 
 
    +  Cases who did not have lymphedema at the time of measurements (n=3). 
 
 Cases Controls Unsure 
Affected or  
at-risk limb 
(Right:Left:Both) 
6R:7L:2B 23R:26L:3B 4R:5L:1B 
Impedance ratio (SD) 1.139 (0.15)     1.076 (0.063)+ 1.008 (0.054) 1.021 (0.025) 
Arm volume++ (SD) 
Affected         Unaffected 
2857 (879)       2754 (701) 
2827 (1178)+     2863 (1274)+ 
At-risk           No risk 
2461 (655)    2433 (737) 
At-risk           No risk 
2590 (346)   2531 (318) 
Volume difference between 
arms (SD) 
103 (278) 
-36 (211)+ 28 (188) 59 (189) 
Limb dominance+++ (R:L)  6R:1L  
Volume difference between 
dominant and non-dominant 
arm (SD) 
 48 (122)  
   + +Arm volumes measured in ml. 
   ++ +Only 7 participants were evaluated for limb dominance. 
 
Table 9. Comparison of impedance ratios. 
Group 
Assignment n Impedance ratio  Std. Deviation F p 
Cases 
 
Cases+  
 
Controls 
 
Unsure 
 
10 
 
3 
 
46 
 
7 
 
1.139  
 
1.076 
 
1.008 
 
1.021  
 
0.15 
 
0.063 
 
0.054 
 
0.025 
 
11.994 <0.01*
            +Cases who did not have lymphedema at the time of measurements. 
 *p<0.05 (2-tailed) 
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5.0  DISCUSSION 
Secondary lymphedema is one of the most under-researched and poorly understood 
complications of breast cancer treatment. Approximately 20% of breast cancer survivors will 
develop lymphedema and be at risk for debilitating arm swelling, functional impairment, 
psychological stress, and diminished quality of life.6 In the past the assumption was that breast 
cancer treatment, specifically the trauma of surgery as well as exposure to radiation, was solely 
responsible for lymphedema onset. While it is accepted that these treatments can cause swelling 
initially, research has failed to provide strong evidence linking treatment alone to the 
development of secondary lymphedema.  
Currently there is no model that exists to predict who will be affected with lymphedema 
after treatment for breast cancer. Obesity and infection are the only two external factors that have 
consistently been shown to increase a woman’s risk for this condition. It is important to identify 
and better understand additional predisposing factors, such as inherent lymphatic variation and 
genetic etiology, in order to help prevent the onset, diagnose it as early as possible, and minimize 
the effects of this debilitating condition.  
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5.1 GENE SEQUENCING 
The investigation of the genetic etiology of secondary lymphedema is an extension of the 
investigations into the genetics of primary lymphedema. Researchers have discovered that 
primary lymphedema is caused in part by mutations in specific genes, FLT4 (VEGFR3), FOXC2, 
and SOX18. In addition, the recent identification of mutations in the HGF/MET pathway 
provides evidence for a parallel mechanism contributing to both primary and secondary 
lymphedema.36 The primary aim of this study was to identify additional genes that may increase 
susceptibility to developing secondary lymphedema. We anticipated that previously unidentified 
genetic variations in connexin genes would be found in women with secondary lymphedema that 
would not be present in control individuals. The connexins are a family of complex genes that 
serve as intercellular channels and facilitate communication between cells. Connexins are present 
in many different tissues and have been implicated in several developmental processes, but the 
details of their regulation are not well understood.  
Four different connexin genes were sequenced: connexin 47 (GJA12), connexin 37 
(GJA4), connexin 40 (GJA5), and exon 2 of connexin 43 (GJA1). Five previously unrecognized 
nucleotide variations were found in connexin 47 in women who had developed lymphedema 
after breast cancer treatment (Table 6). Four of these changes are missense mutations and the 
other is a synonymous substitution. The missense mutation that results in a G149S substitution 
was also seen in a woman with primary lymphedema and her unaffected son. In addition, the 
H198H synonymous substitution has been identified in 9 out of 140 individuals with primary 
lymphedema, and was found in one individual out of 35 without lymphedema. 
A mutation is considered causal when it meets the following four criteria: (1) it is found 
only in lymphedema probands and their at-risk family members, (2) it is not present in over 300 
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chromosomes from ethnically matched controls, (3) it causes a truncation or missense mutation 
in evolutionary conserved regions of the protein, and (4) it is not present in public databases of 
population polymorphisms. At this point, more research is necessary in order to classify the 
missense mutations as being causal, but the results from this study indicate that their role in 
lymphedema is compelling and warrants further investigation. The mutations have not been 
previously identified and were not found in any of the over 100 controls that were tested, which 
implies that they are not common polymorphisms. Future studies are necessary to determine 
whether the mutations are located in a functional domain of the protein and whether the peptide 
changes cause alterations in the protein structure or the channel kinetics. It is known that all of 
the altered peptides in this study are in a region of the protein channel that is located in the 
cytoplasm (UniProtKB/Swiss-Prot). Certain mutations involved in altering peptides located in 
the transmembrane region of the protein channel cause the autosomal recessive condition, 
Pelizaeus-Merzbacher-like disease type I (PMLD1). PMLD1 is a hypomyelinating 
leukodystrophy that is associated with impaired motor development, ataxia, progressive 
spasticity, and nystagmus.43 Further investigations into the effects peptide substitutions have in 
other parts of connexin 47, including the cytoplasm region, are necessary to provide an 
understanding of the role this protein may play in the development of lymphedema. 
The synonymous H198H substitution was identified in five women with secondary 
lymphedema and two who are at-risk but have not developed it. It was also identified in 
individuals with a variety of different forms of primary lymphedema including congenital 
lymphedema, lymphedema praecox, lymphedema tarda with yellow nails, and congenital 
lymphedema with pulmonary lymphangiectasia. The nucleotide change involved is not a splice 
site mutation, which makes it unlikely, although not impossible, that the variation alters the 
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protein. Only 35 controls have been sequenced and many more will need to be evaluated before 
an interpretation of the effects of this nucleotide change can be made with more certainty. 
 
5.2 FLUID AND VOLUME MEASUREMENTS 
The second aim of this study was to examine the arm volumes of participants with and without 
secondary lymphedema using BIS and perometry. We expected that participants with 
lymphedema would have increased fluid and volume measurements in the affected arm 
compared to the contralateral arm, and that the differences between arms would be greater than 
what is present in women who have not developed secondary lymphedema. Statistical analysis of 
the BIS data was consistent with our hypothesis. Interestingly, fluid measurements of women 
who did not have lymphedema at the time of BIS measurement but developed it later were not 
significantly different from women with lymphedema. It is possible that BIS could be sensitive 
enough to detect subclinical swelling prior to the onset of lymphedema; however, these results 
should be interpreted with caution because of the limited number of women in the sample (n=3). 
Further research on BIS measurements are necessary to examine the potential benefits of its use 
in identifying individuals at the highest risk of developing lymphedema based on early fluid 
levels in the upper extremities. 
A comparison of arm differences with the perometer was not significant between cases 
and controls, although cases tended to have the highest volume difference between their arms. 
This was expected because arms affected with lymphedema are typically greater in volume than 
contralateral arms due to the accumulation of fluid. The analysis of the perometer data is 
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complicated by several limitations. One of the limitations is that women with lymphedema did 
not remove their compression garments until the time of measurement. Compression garments 
function to reduce fluid build-up and keep the volume of the arm much lower than it would be 
without the garment. It is likely that without compression the affected arms would have had 
increased volume and fluid measurements than what we were able to capture. These analyses are 
also limited by the absence of information regarding dominance. Dominant arms are often larger 
than non-dominant arms and should be controlled for in future studies examining perometer 
measurements. 
5.3 LIMITATIONS 
This study is limited by the number of cases available for sequencing and the uncertainty of 
identifying individuals as cases or controls. Many women who are considered control 
participants because they have not developed lymphedema are still at risk and may become 
affected in the future, which would alter some of these analyses. This is a particular concern in 
the prospective sample (Group B) because the majority of participants are still within one year of 
surgery. Group B also had a number of individuals who were suspected of having symptoms of 
lymphedema but had not been clinically diagnosed. We accounted for this in most of the 
analyses by creating a separate “unsure” category. We will continue to follow this group in order 
to adjust for changes in their lymphedema status. Difficulty in accurately diagnosing 
lymphedema in research participants has been a complication for many studies and hopefully 
will improve as technology used to diagnose lymphedema advances. It will also be important to 
continue sequencing known cases in order to provide more information about the connexins and 
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to investigate additional genes of interest. As previously discussed, the interpretation of the 
measurement data is limited by the absence of information on arm dominance and the use of 
compression garments by affected participants. Arm dominance will need to be accounted for in 
future studies and analyses.  
 
5.4 CONCLUSIONS 
Despite the limitations, this study does contribute to the present knowledge of lymphedema 
genetics and advances our understanding of the role of connexins in secondary lymphedema. If 
the connexin mutations discussed are in fact causal, it could have an impact on how women with 
breast cancer are currently treated and managed. The ability to predict who is at the greatest risk 
based on genetic factors will help to identify the condition earlier, improve treatment, and 
possibly prevent the onset. This study brings the field closer to having this ability, but more 
research is necessary to expand on these results in order for them to eventually lead to clinical 
benefits. 
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